Patents by Inventor Harald Althaus

Harald Althaus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for quantitatively determining a therapeutic TNF-alpha inhibitor
    Patent number: 11953503
    Abstract: Provided is a universal method for quantitatively determining therapeutic tumor necrosis factor (TNF)-alpha inhibitors in patient samples that is sufficiently sensitive for being able to detect all therapeutic TNF-alpha inhibitors.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: April 9, 2024
    Assignee: Siemens Healthcare Diagnostics Products GmbH
    Inventors: Harald Althaus, Thorsten Keller
  • Binding assay for the diagnosis of a heparin-induced thrombocytopenia
    Patent number: 11320439
    Abstract: The present disclosure is in the field of in vitro diagnostics and relates to an easily automatable binding assay for establishing a heparin-induced thrombocytopenia, which binding assay uses Fc?RIIa protein-coated particles.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: May 3, 2022
    Assignee: Siemens Healthcare Diagnostics Products GmbH
    Inventors: Harald Althaus, Herbert Schwarz, Norbert Zander
  • Activation assay for the diagnosis of a heparin-induced thrombocytopenia
    Patent number: 11262357
    Abstract: The present invention relates to a functional, easily automatable assay for establishing a heparin-induced thrombocytopenia (HIT). What is measured is the secretion of PF4 (platelet factor 4) from activated thrombocytes.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: March 1, 2022
    Assignee: Siemens Healthcare Diagnostics Products GmbH
    Inventors: Harald Althaus, Gerlinde Christ, Herbert Schwarz, Michaela Wicke, Norbert Zander
  • METHOD FOR QUANTITATIVELY DETERMINING A THERAPEUTIC TNF-ALPHA INHIBITOR
    Publication number: 20200400681
    Abstract: The invention is in the field of in vitro diagnostics and relates to a method for quantitatively determining therapeutic TNF-alpha inhibitors.
    Type: Application
    Filed: January 14, 2019
    Publication date: December 24, 2020
    Inventors: Harald ALTHAUS, Thorsten KELLER
  • Methods and kits for determining von willebrand factor activity in the absence of ristocetin
    Patent number: 10591490
    Abstract: Described herein are method(s), kit(s), reagent(s) and the like for determining von Willebrand factor (VWF) activity in a sample in the absence of ristocetin.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: March 17, 2020
    Assignee: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH
    Inventors: Harald Althaus, Tobias Obser, Juergen Patzke, Reinhard Schneppenheim
  • BINDING ASSAY FOR THE DIAGNOSIS OF A HEPARIN-INDUCED THROMBOCYTOPENIA
    Publication number: 20190041398
    Abstract: The present disclosure is in the field of in vitro diagnostics and relates to an easily automatable binding assay for establishing a heparin-induced thrombocytopenia, which binding assay uses Fc?RIIa protein-coated particles.
    Type: Application
    Filed: July 27, 2018
    Publication date: February 7, 2019
    Inventors: Harald ALTHAUS, Herbert SCHWARZ, Norbert ZANDER
  • Activation Assay For The Diagnosis Of A Heparin-Induced Thrombocytopenia
    Publication number: 20180356416
    Abstract: The present invention relates to a functional, easily automatable assay for establishing a heparin-induced thrombocytopenia (HIT). What is measured is the secretion of PF4 (platelet factor 4) from activated thrombocytes.
    Type: Application
    Filed: June 8, 2018
    Publication date: December 13, 2018
    Inventors: Harald Althaus, Gerlinde Christ, Herbert Schwarz, Michaela Wicke, Norbert Zander
  • Methods And Kits For Determining Von Willebrand Factor Activity In The Absence Of Ristocetin
    Publication number: 20180088133
    Abstract: Described herein are method(s), kit(s), reagent(s) and the like for determining von Willebrand factor (VWF) activity in a sample in the absence of ristocetin.
    Type: Application
    Filed: December 8, 2017
    Publication date: March 29, 2018
    Applicant: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH
    Inventors: Harald Althaus, Tobias Obser, Juergen Patzke, Reinhard Schneppenheim
  • Methods and kits for determining von Willebrand factor activity in the absence of ristocetin
    Patent number: 9869683
    Abstract: Described herein are method(s), kit(s), reagent(s) and the like for determining von Willebrand factor (VWF) activity in a sample in the absence of ristocetin.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: January 16, 2018
    Assignee: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH
    Inventors: Harald Althaus, Tobias Obser, Juergen Patzke, Reinhard Schneppenheim
  • Binding partners of the placental growth factor, especially antibodies directed against the placental growth factor, and production and use thereof
    Patent number: 9469687
    Abstract: The invention relates to binding partners of the placental growth factor (or placenta growth factor, PIGF), especially antibodies directed against the placental growth factor, and production and use thereof.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: October 18, 2016
    Assignee: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH
    Inventors: Frank Vitzthum, Stefan Teigelkamp, Harald Althaus
  • Binding partners of the placental growth factor, especially antibodies directed against the placental growth factor, and production and use thereof
    Patent number: 9453071
    Abstract: The invention relates to binding partners of the placental growth factor (or placenta growth factor, PlGF), especially antibodies directed against the placental growth factor, and production and use thereof.
    Type: Grant
    Filed: May 8, 2006
    Date of Patent: September 27, 2016
    Assignee: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH
    Inventors: Frank Vitzthum, Stefan Teigelkamp, Harald Althaus
  • Methods And Kits For Determining Von Willebrand Factor Activity In The Absence Of Ristocetin
    Publication number: 20160231331
    Abstract: Described herein are method(s), kit(s), reagent(s) and the like for determining von Willebrand factor (VWF) activity in a sample in the absence of ristocetin.
    Type: Application
    Filed: December 10, 2015
    Publication date: August 11, 2016
    Applicant: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH
    Inventors: Harald Althaus, Tobias Obser, Juergen Patzke, Reinhard Schneppenheim
  • Methods and kits for determining von willebrand factor activity in the absence of ristocetin
    Patent number: 9222942
    Abstract: Described herein are method(s), kit(s), reagent(s) and the like for determining von Willebrand factor (VWF) activity in a sample in the absence of ristocetin.
    Type: Grant
    Filed: January 6, 2010
    Date of Patent: December 29, 2015
    Assignee: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH
    Inventors: Harald Althaus, Tobias Obser, Juergen Patzke, Reinhard Schneppenheim
  • BINDING PARTNERS OF THE PLACENTAL GROWTH FACTOR, ESPECIALLY ANTIBODIES DIRECTED AGAINST THE PLACENTAL GROWTH FACTOR, AND PRODUCTION AND USE THEREOF
    Publication number: 20150299308
    Abstract: The invention relates to binding partners of the placental growth factor (or placenta growth factor, PIGF), especially antibodies directed against the placental growth factor, and production and use thereof.
    Type: Application
    Filed: June 1, 2015
    Publication date: October 22, 2015
    Inventors: Frank Vitzthum, Stefan Teigelkamp, Harald Althaus
  • Antibodies for determining the prothrombin fragment F2/F1+2 in a homogeneous immunoassay
    Patent number: 9096674
    Abstract: The present invention is in the area of coagulation analysis and relates to antibodies which bind specifically to an immune complex of prothrombin fragment F2/F1+2 and an F2/F1+2 neoepitope-specific antibody fragment, and to the preparation and the use thereof in methods for determining F2/F1+2.
    Type: Grant
    Filed: September 24, 2009
    Date of Patent: August 4, 2015
    Assignee: Siemens Healthcare Diagnostics Products GmbH
    Inventors: Matthias Ehm, Bodo Fischer, Harald Althaus, Roland Barten
  • Methods and kits for determining von Willebrand factor activity in the absence of ristocetin and for determining the activity of ADAMTS-13 protease
    Patent number: 8932820
    Abstract: Described herein are method(s), kit(s), reagent(s) and the like for determining von Willebrand factor (VWF) activity in a sample in the absence of ristocetin.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: January 13, 2015
    Assignee: Siemens Healthcare Diagnostics Products GmbH
    Inventors: Harald Althaus, Tobias Obser, Juergen Patzke, Reinhard Schneppenheim
  • METHODS AND KITS FOR DETERMINING VON WILLEBRAND FACTOR ACTIVITY IN THE ABSENCE OF RISTOCETIN AND FOR DETERMINING THE ACTIVITY OF ADAMTS-13 PROTEASE
    Publication number: 20130078652
    Abstract: Described herein are method(s), kit(s), reagent(s) and the like for determining von Willebrand factor (VWF) activity in a sample in the absence of ristocetin.
    Type: Application
    Filed: September 13, 2012
    Publication date: March 28, 2013
    Inventors: Harald Althaus, Tobias Obser, Juergen Patzke, Reinhard Schneppenheim
  • Peptides with the marburg I polymorphism of factor VII-activating protease (FSAP) and their preparation and uses
    Patent number: 7951910
    Abstract: The invention relates to peptides with the Marburg I polymorphism of FSAP and to their preparation and uses, in particular in therapy and diagnosis. The peptides are suitable for use as immunizing antigens for preparing FSAP MR I specific antibodies.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: May 31, 2011
    Assignee: Siemens Healthcare Diagnostics Products GmbH
    Inventors: Herbert Schwarz, Harald Althaus, Bodo Fischer, Thomas Wissel
  • ANTIBODIES WHICH ARE DIRECTED AGAINST THE MARBURG I POLYMORPHISM OF FACTOR VII-ACTIVATING PROTEASE (FSAP), AND THEIR PREPARATION AND USE
    Publication number: 20100145009
    Abstract: The invention relates to antibodies which are directed against the FSAP Marburg I variant and to their preparation and use, in particular in therapy and diagnosis. The antibodies are characterized by the fact that they bind specifically to the FSAP MR I variant but not to the FSAP wild-type protein or other mutant variants which are characterized by amino acid substitutions at other positions in the FSAP protein.
    Type: Application
    Filed: October 13, 2009
    Publication date: June 10, 2010
    Inventors: Herbert SCHWARZ, Harald ALTHAUS, Bodo Fischer, Thomas WISSEL
  • Methods and Kits for Determining von Willebrand Factor Activity in the Absence of Ristocetin and for Determining the Activity of ADAMTS-13 Protease
    Publication number: 20100136589
    Abstract: Described herein are method(s), kit(s), reagent(s) and the like for determining von Willebrand factor (VWF) activity in a sample in the absence of ristocetin.
    Type: Application
    Filed: January 6, 2010
    Publication date: June 3, 2010
    Inventors: Harald Althaus, Tobias Obser, Juergen Patzke, Reinhard Schneppenheim